2016 prize winners

ACP McElwain Prize
AstraZeneca Young Investigator Prize
British Association of Cancer Research (BACR)/Gordon Hamilton-Fairley Young Investigator Award
British Association of Cancer Research (BACR) AstraZeneca Young Scientist Frank Rose Award
British Association of Cancer Research (BACR) Roger Griffin Prize for Cancer Drug Discovery
Cancer Research UK Future Leaders in Cancer Research Prize
Cancer Research UK Jane Wardle Prevention & Early Diagnosis Prize
Cancer Research UK Lifetime Achievement in Cancer Research Prize
Children’s Cancer and Leukaemia Group (CCLG) McElwain Award
The Company of Biologists Travel Awards
European Association for Cancer Research Travel Awards
National Cancer Research Institute (NCRI) Prize Awards
National Cancer Research Institute (NCRI) Werth Trust Award
Royal College of Radiologists Ross Prizes

ncri-2016-day-3_simon-callaghan-photography_321 ncri-2016-day-3_simon-callaghan-photography_245 ncri-2016-day-3_simon-callaghan-photography_204 ncri-2016-day-2-simon-callaghan-photography-247ncri-2016-day-1-simon-callaghan-photography-131 ncri-2016-day-1-simon-callaghan-photography-127

 

ACP McElwain Prize

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Andrew Furness, University College London Cancer Institute, UK

 

AstraZeneca Young Investigator Poster Prize

A novel oncogene-selective sensitivity to synchronous ferroptotic cell death following nutrient modulation

Ioannis Poursaitidis, University of Liverpool, UK

 

British Association of Cancer Research (BACR) Gordon Hamilton-Fairley Young Investigator Award

Clonal interactions as mechanisms of polyclonality in colorectal adenomas

Viola Walther, Barts Cancer Institute, Queen Mary University London

 

British Association of Cancer Research (BACR) AstraZeneca Young Scientist Frank Rose Award

Cancer specific non-essential amino acid metabolism – a role for targeted dietary intervention in cancer therapy?

Oliver Maddocks, University of Glasgow, UK

 

British Association of Cancer Research (BACR) Roger Griffin Prize for Cancer Drug Discovery

Engineering potency and selectivity of chemical probes for functional elucidation and target validation

Matthias Baud, University of Southampton, UK

 

Cancer Research UK Future Leaders in Cancer Research Prize

Yoryos Lyratzopoulos, University College London

Florian Markowetz, CRUK Cambridge Institute

Andrea Sottoriva, Institute of Cancer Research

 

Cancer Research UK Jane Wardle Prevention & Early Diagnosis Prize

Jo Waller, University College London

 

Cancer Research UK Lifetime Achievement in Cancer Research Prize

Drug development and ovarian cancer – Lessons and personal reflections from a 40-year journey

Stan Kaye, Royal Marsden NHS Foundation Trust, UK

 

Children’s Cancer and Leukaemia Group (CCLG) McElwain Award

Proffered paper: Inhibiting HOX-PBX binding in paediatric glioblastoma as a novel therapeutic treatment

William Rogers, University of Surrey, UK

 

The Company of Biologists Travel Awards

TMEPAI, a novel therapeutic target in triple negative breast cancer prevention and therapy

Prajjal Singha, University of Texas Health Science Center, San Antonio, USA

Disulfiram with or without metformin exhibits potent anti-cancer effects toward oesophageal squamous cell carcinoma in vivo

Rupal Jivan, University of the Witwatersrand, Johannesburg, South Africa

Cervical cancer survival among women referred to cancer centres in Ghana
Yvonne Nartey, University of Otago, New Zealand

Dual inhibition of the MEK5 and PI3K pathways synergistically reduces proliferation and viability in triple negative breast cancer cells
Thomas Wright, Duquesne University, Pittsburgh, USA

Outcome of open distal pancreatectomy: An audit at tertiary care hospital
Amyna Jiwani, Aga Khan University Hospital, Karachi, Pakistan

Effect of melatonin treatment on the intratumour heterogeneity in breast cancer model
André de Lima Mota, Faculdade de Medicina de São José do Rio Preto – FAMERP, Brazil

 

European Association for Cancer Research Travel Awards

Axl promotes metastasis of pancreatic cancer by regulating an EMT programm
Lankhanh Trinh, Rechts der Isar Hospital, Germany

Administration-specific migration of Th1 cells modulates the host immune system, tumour microenvironment, and antitumoural efficiency during immunotherapy in pancreatic cancer
Christoph Griessinger, University of Tübingen, Germany

 

National Cancer Research Institute (NCRI) Prize Awards

Novel serum circulating miRNAs signatures for NSCLC treatment outcome
Julija Fadejeva, Vilnius University Joint Life Sciences Center, Lithuania

A novel NGS based cancer genetic testing solution on highthroughput sequencer BGISEQ-500
Shida Zhu, BGI, China

Endoscopic management of gastrointestinal bleeding in cancer patients with severe thrombocytopenia
Paul Hampel, Mayo School of Graduate Medical Education, USA

Detection of Circulating Tumour Cells for use as prognostic, predictive and pharmacodynamic biomarkers in neuroblastoma
Swathi Merugu, Newcastle University, UK

Metabolism biomarkers measured before prostate cancer diagnosis and second primary tumours: a prospective study in the Swedish AMORIS cohort
Cecilia Bosco, King’s College London, UK

Capture of circulating tumour cells with epithelial and mesenchymal features for prostate cancer prognosis
Lei Xu, Barts Cancer Institute, London, UK

 

National Cancer Research Institute (NCRI) Werth Trust Award

Enhancing responses to melanoma therapy with novel combinations of targeted therapy and immune checkpoint blockade
Robert Szczepaniak Sloane, The University of Texas MD Anderson Cancer Center, USA

 

Royal College of Radiologists (RCR) Ross Prizes

Two prizes are awarded annually at the NCRI Cancer Conference: One for the best poster and one for the best proffered paper presentation.

Oral winner: A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic nodal irradiation

Ciara Lyons, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, UK

Poster winner: A hypoxia transcriptomic signature predicting benefit from hypoxia-modifying treatment for high risk bladder cancer patients

Lingjian Yang, University of Manchester, UK